Vmbook Online ordering

Xencor Inc

Xencor, Inc. is a public company listed on the NASDAQ stock exchange under the ticker symbol "XNCR." The company is a clinical-stage biopharmaceutical company that focuses on developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Xencor's product candidates are designed to optimize the autoimmune response and minimize inherent toxicity, with the goal of improving patient outcomes and quality of life.

Xencor was founded in 2001 and is headquartered in Monrovia, California. The company has a diverse pipeline of product candidates in various stages of clinical development, including XmAb14045, a CD19-targeted antibody-drug conjugate for the treatment of B-cell malignancies, and XmAb13676, a CD38-targeted antibody-drug conjugate for the treatment of multiple myeloma. Other pipeline candidates include XmAb18087, a BTK inhibitor for the treatment of Systemic Lupus Erythematosus, and XmAb20717, a BCMA-targeted antibody-drug conjugate for the treatment of multiple myeloma.

Xencor's financial performance is reported publicly and can be found on financial websites such as Yahoo Finance or Google Finance. The company has reported net losses in its quarterly and annual financial statements, as it continues to invest in research and development of its product candidates. However, the company's stock price has fluctuated based on the progress of its clinical programs and market sentiment.

There have been no notable legal or regulatory issues involving Xencor, and the company has received support from reputable healthcare-focused institutional investors. Xencor has also collaborated with major pharmaceutical companies, such as Amgen and Merck, to advance its product candidates. Overall, Xencor is a development-stage biotech company with promising product candidates in various stages of clinical development, and its stock is closely watched by investors seeking exposure to the biotechnology sector.